Page 19 - Recursion Pharmaceuticals News Today

Don't rush to buy shares just yet.

The popular growth investor keeps adding to some of her favorite stocks.

Cathie Wood just gave the company a huge vote of confidence.

The acceleration of Genentech’s machine learning (ML) capabilities will take place on Nvidia’s DGX Cloud. This includes Nvidia BioNemo, which uses generative AI applications in drug discovery.

In a notable insider transaction, Shafique Virani, the Chief Business Officer of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 18,000 shares of the company on November 15, 2023.

Allspring Global Investments Holdings LLC lifted its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 453.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,073 shares of the company’s stock after acquiring an additional 6,615 shares during the quarter. Allspring […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) CFO Michael Secora sold 25,000 shares of the company’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $6.32, for a total value of $158,000.00. Following the transaction, the chief financial officer now owns 925,686 shares of the company’s […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) shot up 12.7% during mid-day trading on Wednesday . The stock traded as high as $7.31 and last traded at $7.28. 1,168,220 shares were traded during mid-day trading, a decline of 64% from the average session volume of 3,254,322 shares. The stock had previously closed at $6.46. […]

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) traded up 12.7% on Wednesday . The stock traded as high as $7.31 and last traded at $7.28. 1,168,220 shares were traded during mid-day trading, a decline of 64% from the average session volume of 3,254,322 shares. The stock had previously closed at $6.46. Wall […]

In a notable insider transaction, CFO Michael Secora of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) sold 50,000 shares of the company's stock on November 15, 2023.